

## PRODUCT INFORMATION

<b>Common Name</b>	BGB-A317;BGB-A317;TEVIMBRA;Tilelizumab;VDT-482;VDT482;VDT482
<b>Conjugate</b>	Unconjugated
<b>Synonyms</b>	PD1;PD-1;CD279;SLEB2;hPD-1;hPD-1;hSLE1
<b>Applications</b>	N/A
<b>Recommended Dilutions</b>	N/A
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Host Species</b>	N/A
<b>IgG type</b>	IgG4
<b>Reactivity</b>	Human
<b>Target</b>	PD-1
<b>Uniprot ID</b>	Q15116
<b>Description</b>	Anti-PD-1(tislelizumab biosimilar) IgG4) mAb
<b>Delivery</b>	4-6 weeks
<b>Storage&amp;Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
<b>Usage</b>	Research use only

